Ortin Laboratories Key Ratios
NSE: ORTINGLOBE | BSE: 539287
₹14.93
As on 28-Aug-2026IST
Market cap
₹12 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
13.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -94.81 | -80.25 | 37.80 | -58.83 | -69.47 |
| EBIT | -4,075.00 | -106.17 | 2.73 | -241.63 | -169.81 |
| Net Profit | -3,644.44 | -93.68 | 4.27 | -233.71 | -175.72 |
| EPS | -3,634.23 | -93.69 | 2.17 | -237.01 | -183.63 |
| Book Value | -- | -- | -29.97 | -43.49 | -29.60 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| -192.52 | -112.96 | -254.86 | -261.63 | -320.41 |
| Net Margin
| -191.39 | -113.48 | -257.14 | -220.70 | -351.92 |
| Return on equity
| -51.20 | -30.36 | -70.98 | -35.26 | -117.48 |
| Return on Capital
| -27.60 | -15.59 | -- | -24.36 | -60.11 |
| Return on Assets
| -23.63 | -14.29 | -21.35 | -14.82 | -55.63 |
| Debt to Equity (x)
| -- | -- | 0.81 | 0.13 | 0.64 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
-24.36
|
-60.11
|
1.66
|
1.56
|
|
Peer Median
|
--
|
14.72
|
18.85
|
11.60
|
--
|
ROE
-70.98
Lower than Peers by 81.84
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-70.98
|
-35.26
|
-117.48
|
-0.86
|
-3.57
|
|
Peer Median
|
10.86
|
11.67
|
14.92
|
11.46
|
--
|
ROA
-21.35
Lower than Peers by 28.09
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-21.35
|
-14.82
|
-55.63
|
-0.45
|
-1.90
|
|
Peer Median
|
6.74
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
-254.86
Lower than Peers by 267.55
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-254.86
|
-261.63
|
-320.41
|
4.49
|
0.99
|
|
Peer Median
|
12.69
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
-257.14
Lower than Peers by 266.00
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-257.14
|
-220.70
|
-351.92
|
-1.54
|
-4.73
|
|
Peer Median
|
8.86
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
-243.92
|
-370.00
|
2.60
|
-1.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
37.80
Higher than Peers by 29.66
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
37.80
|
-83.79
|
-64.93
|
-26.86
|
0.78
|
|
Peer Median
|
8.14
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
2.73
Lower than Peers by 14.52
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
2.73
|
86.77
|
-2,600.18
|
231.21
|
-91.49
|
|
Peer Median
|
17.24
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
4.27
Lower than Peers by 12.59
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
4.27
|
89.47
|
-8,490.81
|
76.52
|
-142.17
|
|
Peer Median
|
16.85
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
2.17
Lower than Peers by 8.43
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
2.17
|
89.47
|
-8,491.49
|
76.52
|
-142.17
|
|
Peer Median
|
10.60
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
-29.97
|
-74.01
|
-0.84
|
-3.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.81
Higher than Peers by 0.77
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
0.81
|
0.13
|
0.64
|
0.59
|
0.56
|
|
Peer Median
|
0.04
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
--
|
--
|
0.32
|
0.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.60
Lower than Peers by 0.12
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
1.60
|
2.15
|
2.36
|
0.94
|
0.76
|
|
Peer Median
|
1.72
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
1.60
Higher than Peers by 0.42
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
1.60
|
2.14
|
2.35
|
0.56
|
0.53
|
|
Peer Median
|
1.17
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
-892.00
Lower than Peers by 899.86
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-892.00
|
-309.19
|
-13.68
|
0.72
|
0.34
|
|
Peer Median
|
7.86
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
57.43
Higher than Peers by 31.64
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
57.43
|
76.33
|
83.66
|
56.76
|
39.32
|
|
Peer Median
|
25.79
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
0.08
Lower than Peers by 0.58
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
0.08
|
0.06
|
0.15
|
0.29
|
0.39
|
|
Peer Median
|
0.67
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
1,081.40
|
448.05
|
201.69
|
158.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
37.33
|
228.92
|
131.55
|
79.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
102.48
|
79.84
|
125.69
|
83.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
1,016.26
|
597.13
|
207.55
|
154.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-13.46
Lower than Peers by 53.36
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-13.46
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.90
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
13.41
Higher than Peers by 9.18
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
13.41
|
4.10
|
5.13
|
1.30
|
1.68
|
|
Peer Median
|
4.23
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
-14.03
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
-14.03
|
-9.49
|
-2.19
|
36.13
|
41.98
|
|
Peer Median
|
--
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
12
Lower than Peers by 7,600
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Ortin Laboratories
|
12
|
8
|
14
|
14
|
18
|
|
Peer Median
|
7,613
|
4,851
|
2,099
|
15,272
|
--
|